Aurora kinase inhibitor patents and agents in clinical testing: An update (2009 - 10)

Expert Opinion on Therapeutic Patents

Volumn 21, Issue 6, 2011, Pages 857-884

  Cheung, Chun Hei Antonio ^a   Coumar, Mohane Selvaraj ^b   Chang, Jang Yang ^a   Hsieh, Hsing Pang ^a  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^b PONDICHERRY UNIVERSITY   (India)

Author keywords

AMG 900; AT 9283; aurora kinase inhibitors; AZD1152; BI811283; CYC116; ENMD 2076; GSK1070916; MLN8054; MLN8237; PF 3814735; PHA739358; R763; SNS 314; VX 680 MK0457; VX 689 MK 5108; XL228

Indexed keywords

1 CYCLOPROPYL 3 [3 (5 MORPHOLINOMETHYL 1H BENZIMIDAZOL 2 YL) 1H PYRAZOL 4 YL]UREA; 4 [[9 CHLORO 7 (2,6 DIFLUOROPHENYL) 5H PYRIMIDO[5,4 D][2]BENZAZEPIN 2 YL]AMINO]BENZOIC ACID; ALISERTIB; AMG 900; AURORA KINASE INHIBITOR; BARASERTIB; BI 811283; BORTEZOMIB; CENISERTIB; CISPLATIN; CYC 116; CYTARABINE; DANUSERTIB; DASATINIB; DOCETAXEL; ENMD 2076; GEMCITABINE; GSK 1070916; IMATINIB; IRINOTECAN; MK 5108; PACLITAXEL; PF 3814735; SNS 314; TOZASERTIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORINOSTAT; VX 689; WORTMANNIN; XL 228;

ABDOMINAL PAIN; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; BLOOD DISEASE; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONSTIPATION; CONTINUOUS INFUSION; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG RESEARCH; DRUG WITHDRAWAL; DYSPHONIA; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; HUMAN; HYPERTENSION; INFECTION; LEUKEMIA; LEUKOPENIA; LOW DRUG DOSE; MUCOSA INFLAMMATION; MULTIPLE MYELOMA; NATIONAL HEALTH ORGANIZATION; NEUROBLASTOMA; NEUTROPENIA; PANCREAS CANCER; PATENT; QT PROLONGATION; RECOMMENDED DRUG DOSE; REVIEW; SEDATION; SIDE EFFECT; SOLID TUMOR; SOMNOLENCE; SQUAMOUS CELL CARCINOMA; TONGUE CARCINOMA; VOMITING;

CLINICAL TRIALS AS TOPIC; HUMANS; PATENTS AS TOPIC; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES;

EID: 79956223049     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2011.574614     Document Type: Review

References (101)

1. Murata-Hori M, Tatsuka M, Wang YL. Probing the dynamics and functions of aurora B kinase in living cells during mitosis and cytokinesis. Mol Biol Cell 2002;13(4):1099-108 (Pubitemid 34309608)
2. Lu L-Y, Wood JL, Ye L, et al. Aurora A is essential for early embryonic development and tumor suppression. J Biol Chem 2008;283(46):31785-90
3. Vischioni B, Oudejans JJ, Vos W, et al. Frequent overexpression of aurora B kinase, a novel drug target, in non-small cell lung carcinoma patients. Mol Cancer Ther 2006;5(11):2905-13 (Pubitemid 44849018)
4. Dar AA, Zaika A, Piazuelo MB, et al. Frequent overexpression of aurora kinase A in upper gastrointestinal adenocarcinomas correlates with potent antiapoptotic functions. Cancer 2008;112(8):1688-98 (Pubitemid 351536828)
5. Smith SL, Bowers NL, Betticher DC, et al. Overexpression of aurora B kinase (AURKB) in primary non-small cell lung carcinoma is frequent, generally driven from one allele, and correlates with the level of genetic instability. Br J Cancer 2005;93(6):719-29 (Pubitemid 41486464)
6. Kitajima S, Kudo Y, Ogawa I, et al. Constitutive phosphorylation of aurora-a on ser51 induces its stabilization and consequent overexpression in cancer. PLoS One 2007;2(9):e944
7. Harrington EA, Bebbington D, Moore J, et al. VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat Med 2004;10(3):262-7 (Pubitemid 38667616)
8. Tyler RK, Shpiro N, Marquez R, et al. VX-680 inhibits aurora A and aurora B kinase activity in human cells. Cell Cycle 2007;6(22):2846-54 (Pubitemid 350277179)
9. Gizatullin F, Yao Y, Kung V, et al. The Aurora kinase inhibitor VX-680 induces endoreduplication and apoptosis preferentially in cells with compromised p53-dependent postmitotic checkpoint function. Cancer Res 2006;66(15):7668-77 (Pubitemid 44289225)
10. Wilkinson RW, Odedra R, Heaton SP, et al. AZD1152, a selective inhibitor of aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis. Clin Cancer Res 2007;13(12):3682-8 (Pubitemid 46955132)
11. Manfredi MG, Ecsedy JA, Meetze KA, et al. Antitumor activity of MLN8054, an orally active small-molecule inhibitor of aurora A kinase. Proc Natl Acad Sci USA 2007;104(10):4106-11 (Pubitemid 47181586)
12. Hardwicke MA, Oleykowski CA, Plant R, et al. GSK1070916, a potent aurora B/C kinase inhibitor with broad antitumor activity in tissue culture cells and human tumor xenograft models. Mol Cancer Ther 2009;8(7):1808-17
13. Anderson K, Lai Z, McDonald OB, et al. Biochemical characterization of GSK1070916, a potent and selective inhibitor of aurora B and aurora C kinases with an extremely long residence time1. Biochem J 2009;420(2):259-65
14. Hoar K, Chakravarty A, Rabino C, et al. MLN8054, a small-molecule inhibitor of aurora A, causes spindle pole and chromosome congression defects leading to aneuploidy. Mol Cell Biol 2007;27(12):4513-25 (Pubitemid 46906573)
15. Arbitrario JP, Belmont BJ, Evanchik MJ, et al. SNS-314, a pan-aurora kinase inhibitor, shows potent anti-tumor activity and dosing flexibility in vivo. Cancer Chemother Pharmacol 2010;65(4):707-17
16. VanderPorten EC, Taverna P, Hogan JN, et al. The aurora kinase inhibitor SNS-314 shows broad therapeutic potential with chemotherapeutics and synergy with microtubule-targeted agents in a colon carcinoma model. Mol Cancer Ther 2009;8(4):930-9
17. Tao Y, Leteur C, Calderaro J, et al. The aurora B kinase inhibitor AZD1152 sensitizes cancer cells to fractionated irradiation and induces mitotic catastrophe. Cell Cycle 2009;8(19):3172-81
18. Yang J, Ikezoe T, Nishioka C, et al. AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo. Blood 2007;110(6):2034-40 (Pubitemid 47443920)
19. Coumar MS, Cheung CH, Chang JY, et al. Advances in aurora kinase inhibitor patents. Expert Opin Ther Pat 2009;19(3):321-56
20. Cheung CH, Coumar MS, Hsieh HP, et al. Aurora kinase inhibitors in preclinical and clinical testing. Expert Opin Investig Drugs 2009;18(4):379-98
21. Bebbington D, Binch H, Charrier JD, et al. The discovery of the potent aurora inhibitor MK-0457 (VX-680). Bioorg Med Chem Lett 2009;19(13):3586-92
22. Traynor AM, Hewitt M, Liu G, et al. Phase I dose escalation study of MK-0457, a novel aurora kinase inhibitor, in adult patients with advanced solid tumors. Cancer Chemother Pharmacol 2011;67(2):305-14
23. Okabe S, Tauchi T, Ohyashiki K. Efficacy of MK-0457 and in combination with vorinostat against Philadelphia chromosome positive acute lymphoblastic leukemia cells. Ann Hematol 2010;89(11):1081-7
24. Yao JE, Yan M, Guan Z, et al. Aurora-A down-regulates IkappaBalpha via Akt activation and interacts with insulin-like growth factor-1 induced phosphatidylinositol 3-kinase pathway for cancer cell survival. Mol Cancer 2009;8:95
25. Cheok CF, Kua N, Kaldis P, et al. Combination of nutlin-3 and VX-680 selectively targets p53 mutant cells with reversible effects on cells expressing wild-type p53. Cell Death Differ 2010;17(9):1486-500
26. Pluim D, Beijnen JH, Schellens JH, et al. Simultaneous determination of AZD1152 (prodrug) and AZD1152-hydroxyquinazoline pyrazol anilide by reversed phase liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci 2009;877(29):3549-55
27. Tomita M, Tanaka Y, Mori N. Aurora kinase inhibitor AZD1152 negatively affects the growth and survival of HTLV-1-infected T lymphocytes in vitro. Int J Cancer 127(7):1584-94
28. Gully CP, Zhang F, Chen J, et al. Antineoplastic effects of an Aurora B kinase inhibitor in breast cancer. Mol Cancer 2010;9:42
29. Aihara A, Tanaka S, Yasen M, et al. The selective aurora B kinase inhibitor AZD1152 as a novel treatment for hepatocellular carcinoma. J Hepatol 2010;52(1):63-71
30. Nair JS, de Stanchina E, Schwartz GK. The topoisomerase I poison CPT-11 enhances the effect of the aurora B kinase inhibitor AZD1152 both in vitro and in vivo. Clin Cancer Res 2009;15(6):2022-30
31. Li J, Anderson MG, Tucker LA, et al. Inhibition of aurora B kinase sensitizes a subset of human glioma cells to TRAIL concomitant with induction of TRAIL-R2. Cell Death Differ 2009;16(3):498-511
32. Boss DS, Witteveen PO, van der Sar J, et al. Clinical evaluation of AZD1152, an i.v. inhibitor of aurora B kinase, in patients with solid malignant tumors. Ann Oncol 2011;22(2):431-7
33. Kuo CC, Hsieh HP, Pan WY, et al. BPR0L075, a novel synthetic indole compound with antimitotic activity in human cancer cells, exerts effective antitumoral activity in vivo. Cancer Res 2004;64(13):4621-8
34. Guo J, Anderson MG, Tapang P, et al. Identification of genes that confer tumor cell resistance to the aurora B kinase inhibitor, AZD1152. Pharmacogenomics J 2009;9(2):90-102
35. Carpinelli P, Ceruti R, Giorgini ML, et al. PHA-739358, a potent inhibitor of aurora kinases with a selective target inhibition profile relevant to cancer. Mol Cancer Ther 2007;6(12 Pt 1):3158-68
36. Fancelli D, Moll J, Varasi M, et al. 1,4,5,6-tetrahydropyrrolo[3,4-c] pyrazoles: identification of a potent aurora kinase inhibitor with a favorable antitumor kinase inhibition profile. J Med Chem 2006;49(24):7247-51
37. Benten D, Keller G, Quaas A, et al. Aurora kinase inhibitor PHA-739358 suppresses growth of hepatocellular carcinoma in vitro and in a xenograft mouse model. Neoplasia 2009;11(9):934-44
38. Cohen RB, Jones SF, Aggarwal C, et al. A phase I dose-escalation study of danusertib (PHA-739358) administered as a 24-hour infusion with and without granulocyte colony-stimulating factor in a 14-day cycle in patients with advanced solid tumors. Clin Cancer Res 2009;15(21):6694-701
39. Steeghs N, Eskens FA, Gelderblom H, et al. Phase I pharmacokinetic and pharmacodynamic study of the aurora kinase inhibitor danusertib in patients with advanced or metastatic solid tumors. J Clin Oncol 2009;27(30):5094-101
40. Nerviano Medical Sciences S.R.L. (IT). WO2010009985A2. 2010
41. Nerviano Medical Sciences S.R.L. (IT). US20100022553A1. 2010
42. Nerviano Medical Sciences S.R.L. (IT). WO2010009967A1. 2010
43. Dar AA, Belkhiri A, Ecsedy J, et al. Aurora kinase A inhibition leads to p73-dependent apoptosis in p53-deficient cancer cells. Cancer Res 2008;68(21):8998-9004
44. Huck JJ, Zhang M, McDonald A, et al. MLN8054, an inhibitor of aurora A kinase, induces senescence in human tumor cells both in vitro and in vivo. Mol Cancer Res 2010;8(3):373-84
45. Sloane DA, Trikic MZ, Chu ML, et al. Drug-resistant aurora A mutants for cellular target validation of the small molecule kinase inhibitors MLN8054 and MLN8237. ACS Chem Biol 2010;5(6):563-76
46. Dees EC, Infante JR, Cohen RB, et al. Phase 1 study of MLN8054, a selective inhibitor of aurora A kinase in patients with advanced solid tumors. Cancer Chemother Pharmacol 2011;67:945-54
47. Macarulla T, Cervantes A, Elez E, et al. Phase I study of the selective aurora A kinase inhibitor MLN8054 in patients with advanced solid tumors: safety, pharmacokinetics, and pharmacodynamics. Mol Cancer Ther 2010;9(10):2844-52
48. Sells TB, Ecsedy JA, Stroud SG. MLN8237: an orally active small molecule inhibitor of aurora A kinase in phase I clinical trials. AACR Annual Meeting (Meeting abstracts); 12 - 16 April 2008; San Francisco, CA, USA
49. Gorgun G, Calabrese E, Hideshima T, et al. A novel aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma. Blood 2010;115(25):5202-13
50. Maris JM, Morton CL, Gorlick R, et al. Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP). Pediatr Blood Cancer 2010;55(1):26-34
51. Wang S, Midgley CA, Scaerou F, et al. Discovery of N-phenyl-4-(thiazol-5- yl) pyrimidin-2-amine aurora kinase inhibitors. J Med Chem 2010;53(11):4367-78
52. Oslob JD, Heumann SA, Yu CH, et al. Water-soluble prodrugs of an aurora kinase inhibitor. Bioorg Med Chem Lett 2009;19(5):1409-12
53. Zhong M, Bui M, Shen W, et al. 2-Aminobenzimidazoles as potent aurora kinase inhibitors. Bioorg Med Chem Lett 2009;19(17):5158-61
54. Adams ND, Adams JL, Burgess JL, et al. Discovery of GSK1070916, a potent and selective inhibitor of aurora B/C kinase. J Med Chem 2010;53(10):3973-4001
55. Jani JP, Arcari J, Bernardo V, et al. PF-03814735, an orally bioavailable small molecule aurora kinase inhibitor for cancer therapy. Mol Cancer Ther 2010;9(4):883-94
56. Bray MR. ENMD-2076, an oral aurora A and angiogenesis kinase inhibitor. AACR Annual Meeting (Meeting abstracts); 12 - 16 April 2008; San Franciso, CA, USA
57. Wang S, Midgley CA, Scaerou F, et al. Discovery of N-phenyl-4-(thiazol-5- yl) pyrimidin-2-amine aurora kinase inhibitors. J Med Chem 2010;53(11):4367-78
58. Tentler JJ, Bradshaw-Pierce EL, Serkova NJ, et al. Assessment of the in vivo antitumor effects of ENMD-2076, a novel multitargeted kinase inhibitor, against primary and cell line-derived human colorectal cancer xenograft models. Clin Cancer Res 2010;16(11):2989-98
59. Yee KWL. A phase I study of ENMD-2076 in patients with relapsed or refractory leukemia. ASH Annual Meeting and Exposition (Meeting abstracts); 4 - 7 December 2010; Orlando, FL, USA.
60. Howard S, Berdini V, Boulstridge JA, et al. Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity. J Med Chem 2009;52(2):379-88
61. Tanaka R, Squires MS, Kimura S, et al. Activity of the multitargeted kinase inhibitor, AT9283, in imatinib-resistant BCR-ABL-positive leukemic cells. Blood 2010;116(12):2089-95
62. Kristeleit R. A phase I study of AT9283, an aurora kinase inhibitor, in patients with refractory solid tumors. ASCO Annual Meeting (Meeting abstracts); 29 May - 2 June 2009; Orlando, FL, USA
63. McLaughlin J, Markovtsov V, Li H, et al. Preclinical characterization of aurora kinase inhibitor R763/ AS703569 identified through an image-based phenotypic screen. J Cancer Res Clin Oncol 2010;136(1):99-113
64. Shimomura T, Hasako S, Nakatsuru Y, et al. MK-5108, a highly selective aurora-A kinase inhibitor, shows antitumor activity alone and in combination with docetaxel. Mol Cancer Ther 2010;9(1):157-66
65. Payton MN, Bush TL, Chung G, et al. Preclinical evaluation of AMG 900, a novel potent and highly selective pan-aurora kinase inhibitor with activity in taxane-resistant tumor cell lines. Cancer Res 2010;70(23):9846-54
66. Gurtler U, Tontsch-Grunt U, Jarvis M, et al. Effect of BI 811283, a novel inhibitor of aurora B kinase, on tumor senescence and apoptosis. J Clin Oncol 2010;28(Suppl):abstract e13632
67. Scheulen ME, Mross KB, Richly H, et al. A phase I dose-escalation study of BI 811283, an aurora B inhibitor, administered days 1 and 15, every four weeks in patients with advanced solid tumors. J Clin Oncol 2010;28(Suppl): abstract e13065
68. Smith DC, Britten C, Garon EB, et al. A phase I study of XL228, a multitargeted protein kinase inhibitor, in patients (pts) with solid tumors or multiple myeloma. J Clin Oncol 2010;28 (15 Suppl):abstract 3105
69. Abbott Laboratories. WO2010065825A2. 2010
70. Banyu Pharmaceutical Co. WO2009104802A1. 2009
71. Banyu Pharmaceutical Co. Ltd. WO08026768A1. 2008
72. Banyu Pharmaceuticals and Vertex Pharmaceuticals. WO2010111050A1. 2010
73. Banyu Pharmaceuticals and Vertex Pharmaceuticals. WO2010111056A1. 2010
74. Banyu Pharmaceuticals andVertex Pharmaceuticals. WO2010111057A1. 2010
75. Merck Serono S.A. WO2009108670A1. 2009
76. Merck Serono S.A. WO2010002779A2. 2010
77. Merck Patent GmbH. WO2010077530A1. 2010
78. Merck Serono S.A. WO2010028116A1. 2010
79. National Health Research Institutes. WO2009134658A2. 2009
80. National Health Research Institutes. WO2010036629A2. 2010
81. Coumar MS, Tsai MT, Chu CY, et al. Identification, SAR studies, and X-ray co-crystallographic analysis of a novel furanopyrimidine aurora kinase A inhibitor. ChemMedChem 2010;5(2):255-67
82. Coumar MS, Chu CY, Lin CW, et al. Fast-forwarding hit to lead: aurora and epidermal growth factor receptor kinase inhibitor lead identification. J Med Chem 2010;53(13):4980-8
83. Schering Corp. & Albany Molecular Research. WO2009097233A1. 2009
84. Schering Corp. WO2009017701A1. 2009
85. University Health Network. WO2009079767A1. 2009
86. University Health Network. WO2010115279A1. 2010
87. Arrow Therapeutics Ltd. WO2009063240A1. 2009
88. Bayer Healthcare LLC. WO2009042543A1. 2009
89. Curis, Inc. WO2009086012A1. 2009
90. Mikana Therapeutics, Inc. WO2010062848A1. 2010
91. Shanghai Genomics, Inc. WO2010051781A1. 2010
92. Telik, Inc. WO2010036873A1. 2010
93. Universitaet Leipzig, Fundacio Privada Centre de Regulacio Genomica and Institucio Catalana de Recerca I Estudis Avancats. WO2010081881A1. 2010
94. Vitae Pharmaceuticals, Inc. WO2009111028A1. 2009
95. Jackson JR, Patrick DR, Dar MM, et al. Targeted anti-mitotic therapies: can we improve on tubulin agents? Nat Rev Cancer 2007;7(2):107-17 (Pubitemid 46160987)
96. Nerviano Medical Sciences S.r.l. US20100022553A1. 2010
97. Nerviano Medical Sciences S.r.l. WO2010009967A1. 2010
98. Moore AS, Blagg J, Linardopoulos S, et al. Aurora kinase inhibitors: novel small molecules with promising activity in acute myeloid and Philadelphia-positive leukemias. Leukemia 2010;24(4):671-8
99. Mahboobi S, Dove S, Sellmer A, et al. Design of chimeric histone deacetylase- and tyrosine kinase-inhibitors: a series of imatinib hybrides as potent inhibitors of wild-type and mutant BCR-ABL, PDGF-Rbeta, and histone deacetylases. J Med Chem 2009;52(8):2265-79
100. Abbott Laboratories. WO2009012312A1. 2009
101. Abbott Laboratories. WO2009136966A1. 2009